Bristol-Myers Squibb bags immunotherapy unicorn – Chemistry World (subscription)
|
Bristol-Myers Squibb bags immunotherapy unicorn
Chemistry World (subscription) US drugmaker Bristol-Myers Squibb (BMS) has agreed to buy Boston-based startup IFM Therapeutics. The deal gives BMS rights to IFM's two preclinical cancer programmes – stimulator of interferon genes (Sting) and NLRP3 agonist drugs that work with the … |
